About the Company
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology. Neuronetics became "first and only Food and Drug Administration (FDA) approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device (FDA approval K061053)."They manufacture a transcranial magnetic stimulation device, NeuroStar. The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head.
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
246
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $STIM News
Neuronetics Inc STIM
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
New Study Offers Hope for Depression Patients Undergoing TMS Therapy
Neuronetics, Inc. (NASDAQ: STIM) has announced the publication of a groundbreaking study in the prestigious journal Brain ...
Neuronetics, Inc. (STIM) Interactive Stock Chart - Yahoo Finance
April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for ...
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
"These findings provide hope for practitioners and patients alike that a lack of improvement early in a TMS treatment regimen does not predict final non-response status, reinforcing the importance of ...
Neuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New Indication
(RTTNews) - Neuronetics, Inc. (STIM) announced clearance from the FDA for NeuroStar Advanced Therapy for use as an adjunct for the treatment of major depressive disorder in adolescent patients ...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer ...
Neurostar cleared for use in adolescent depression
The U.S. FDA granted Neuronetics Inc. clearance for use of its Neurostar advanced therapy as an adjunctive treatment of major depressive disorder in patients aged 15 to 21, making it the first ...
Neuronetics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Neuronetics, Inc. (STIM)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...